On Tuesday, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) was -1.72% drop from the session before settling in for the closing price of $8.71. A 52-week range for ARQT has been $1.76 – $13.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 303.42% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 59.90%. With a float of $101.69 million, this company’s outstanding shares have now reached $116.89 million.
In an organization with 296 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 92.17%, operating margin of -136.13%, and the pretax margin is -147.95%.
Arcutis Biotherapeutics Inc (ARQT) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcutis Biotherapeutics Inc stocks. The insider ownership of Arcutis Biotherapeutics Inc is 13.00%, while institutional ownership is 100.45%. The most recent insider transaction that took place on Oct 01 ’24, was worth 92,616. In this transaction Director of this company sold 10,000 shares at a rate of $9.26, taking the stock ownership to the 181,944 shares. Before that another transaction happened on Oct 02 ’24, when Company’s SVP Chief Commercial Officer sold 3,725 for $10.01, making the entire transaction worth $37,295. This insider now owns 136,635 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 59.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.80% during the next five years compared to -48.07% drop over the previous five years of trading.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
You can see what Arcutis Biotherapeutics Inc (ARQT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.14 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Let’s dig in a bit further. During the last 5-days, its volume was 1.71 million. That was inferior than the volume of 3.28 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 35.93%. Additionally, its Average True Range was 0.53.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 36.18%, which indicates a significant increase from 28.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.67% in the past 14 days, which was lower than the 69.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.74, while its 200-day Moving Average is $9.09. However, in the short run, Arcutis Biotherapeutics Inc’s stock first resistance to watch stands at $8.77. Second resistance stands at $8.99. The third major resistance level sits at $9.21. If the price goes on to break the first support level at $8.33, it is likely to go to the next support level at $8.11. Assuming the price breaks the second support level, the third support level stands at $7.89.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
There are 116,891K outstanding shares of the company, which has a market capitalization of 1.00 billion. As of now, sales total 59,610 K while income totals -262,140 K. Its latest quarter income was 30,860 K while its last quarter net income were -52,330 K.
